ERIS
Eris Lifesciences share price & financials
- Price
- ₹1,448.4
- Market cap
- ₹18.4k Cr
- Sector
- Healthcare
- Calls analysed
- 8
Eris Lifesciences Limited Q1 FY27
What went well
- DBF revenue grew 14% in Q1 FY27, with 7 out of 10 therapies delivering double-digit growth rates.
- Consolidated Revenue grew 13% YoY in Q1 FY27.
- Profit After Tax grew 14-15% in Q1 FY27.
What to watch
- Underperformance in OAD and Cardiac segments, with Cardiac trailing in Hypertension.
- Gross margins saw a sharp sequential decline, attributed to product mix changes and raw material costs.
What Eris Lifesciences Limited does
Eris Lifesciences is an Indian pharmaceutical company that sells branded prescription formulations to doctors and patients through the domestic market, earning the bulk of its revenue from chronic and sub-chronic therapies such as oral anti-diabetes, cardiovascular disease and vitamins/minerals/nutrition (VMN), alongside emerging specialties like dermatology, insulins, women's health, CNS, critical care, nephrology and oncology. It has vertically integrated backward into manufacturing across small-molecule oral solids/liquids, sterile injectables and biologics (insulins, GLP-1 analogues, monoclonal antibodies), largely built through acquisitions (Biocon's India branded-formulations business, Swiss Parenterals, Eris BioNxt, a stake in Levim Lifetech). It is also building an international arm, exporting from its Swiss Parenterals and Ahmedabad sites and pursuing a Europe-focused CDMO business.
Segments
- Domestic Branded Formulations (DBF)
- International Business
- Manufacturing units
- 6 globally accredited/compliant units across 4 states (Ahmedabad x3, Guwahati, Raisen/Bhopal MP, Chennai)
- IPM market rank
- Ranked 20th in the Indian Pharmaceutical Market (IPM); youngest company among the Top-20
- Therapy areas
- Oral Anti-Diabetes, Insulins, Cardiovascular, VMN, Dermatology, Women's Health, CNS, Critical Care, Nephrology, Oncology
- Mother brand portfolio
- Top-25 mother brands, 15 of which rank in the Top-5 of their respective segments
- Prescription rank (Dermatologists)
- #2 nationally
- Prescription rank (Diabetologists/Endocrinologists)
- #5 nationally
Guidance record · Q1 FY27
what the last two calls moved 27 tracked 1 delivered 8 missed 18 open- Consolidated EBITDA Margin delivered said Q2 FY25 Promised: 35% for FY25 Q1 FY27: Target period passed.
- DBF Revenue missed said Q2 FY25 Promised: ₹2,600 crores for FY25 Q1 FY27: Target period passed.
- CDMO Revenue at risk said Q1 FY26 Promised: ₹100 crores revenue for FY27 Q1 FY27: Management states CAPA actions for EU GMP are on track for sites to be audit-ready by Dec 2026. However, FY27 export guidance is now 'flattish', reinforcing the significant risk to this revenue target.
All 27 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue down 23.3%, net profit down 52.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 437 | 400 | 405 | 579 | 650 +49% | 315 −21% | 277 −32% | 444 −23% |
| EBITDA | 143 | 100 | 121 | 216 | 297 +108% | 77 −23% | 22 −82% | 120 −44% |
| Net profit | 28 | 2 | 30 | 100 | 150 +436% | 3 +50% | -9 −130% | 48 −52% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −20.9% 1Y
1Y: ₹1,713.7 on 10 Sept 2025 → ₹1,355.5. High ₹1,713.7 (10 Sept 2025), low ₹1,271 (23 Mar 2026).
How the price took the results
close before → close after
- Q1 FY27
- +2.6%
- 29 Jul
- Q4 FY26
- +9.1%
- 20 May
- Q3 FY26
- −6.4%
- 13 Feb
- Q2 FY26
- −1.3%
- 12 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 2.6% a year over 3 years, FY23 to FY26. Operating margin widened to 33.6%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹1.7k Cr | ₹1.5k Cr | ₹1.7k Cr | ₹1.8k Cr |
| Operating profit | ₹536 Cr | ₹453 Cr | ₹487 Cr | ₹612 Cr |
| Operating margin | 31.8% | 30.5% | 28.7% | 33.6% |
| Interest | ₹26 Cr | ₹58 Cr | ₹220 Cr | ₹179 Cr |
| Depreciation | ₹117 Cr | ₹102 Cr | ₹182 Cr | ₹155 Cr |
| Net profit | ₹373 Cr | ₹301 Cr | ₹77 Cr | ₹244 Cr |
| Net margin | 22.1% | 20.3% | 4.5% | 13.4% |
| Cash from operations | ₹322 Cr | ₹336 Cr | ₹702 Cr | ₹564 Cr |
| Free cash flow | ₹11 Cr | ₹-13 Cr | ₹694 Cr | ₹515 Cr |
| ROCE | 20.0% | 10.0% | 7.0% | 11.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr |
| Reserves | ₹1.6k Cr | ₹1.9k Cr | ₹2.2k Cr | ₹2.5k Cr | ₹3.1k Cr | ₹3.2k Cr |
| Borrowings | ₹0 Cr | ₹0 Cr | ₹317 Cr | ₹2.6k Cr | ₹2.4k Cr | ₹2.1k Cr |
| Other liabilities | ₹179 Cr | ₹232 Cr | ₹245 Cr | ₹254 Cr | ₹1.7k Cr | ₹481 Cr |
| Total liabilities | ₹1.8k Cr | ₹2.1k Cr | ₹2.8k Cr | ₹5.3k Cr | ₹7.2k Cr | ₹5.8k Cr |
| Fixed assets | ₹584 Cr | ₹642 Cr | ₹898 Cr | ₹1.5k Cr | ₹5.2k Cr | ₹2.4k Cr |
| Capital work in progress | ₹2 Cr | ₹3 Cr | ₹0 Cr | ₹1 Cr | ₹122 Cr | ₹0 Cr |
| Investments | ₹531 Cr | ₹778 Cr | ₹997 Cr | ₹1.6k Cr | ₹68 Cr | ₹1.4k Cr |
| Other assets | ₹638 Cr | ₹728 Cr | ₹889 Cr | ₹2.2k Cr | ₹1.8k Cr | ₹2.0k Cr |
| Total assets | ₹1.8k Cr | ₹2.1k Cr | ₹2.8k Cr | ₹5.3k Cr | ₹7.2k Cr | ₹5.8k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, FIIs trimmed −2.63 pp while DIIs added +2.53 pp. The shareholder count shrank 3% to 50,798.
- Promoters
- 54.1%
- FIIs
- 5.8%
- DIIs
- 20.7%
- Public
- 19.4%
Since Jun 2025
- FIIs −2.63 pp
- DIIs +2.53 pp
- Public +0.80 pp
How it drifted, 12 quarters
Over this window FIIs fell from 13.2% to 5.8% — −7.4 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 54.9%, FIIs 13.2%, DIIs 14.5%, Public 17.4%.Dec '23: Promoters 54.9%, FIIs 13.1%, DIIs 14.6%, Public 17.4%.Mar '24: Promoters 54.9%, FIIs 14.3%, DIIs 15.6%, Public 15.2%.Jun '24: Promoters 54.9%, FIIs 14.6%, DIIs 16.2%, Public 14.3%.Sep '24: Promoters 54.9%, FIIs 8.0%, DIIs 18.6%, Public 18.5%.Dec '24: Promoters 54.9%, FIIs 8.4%, DIIs 18.1%, Public 18.7%.Mar '25: Promoters 54.9%, FIIs 8.4%, DIIs 18.1%, Public 18.6%.Jun '25: Promoters 54.8%, FIIs 8.4%, DIIs 18.2%, Public 18.6%.Sep '25: Promoters 54.9%, FIIs 7.2%, DIIs 19.4%, Public 18.6%.Dec '25: Promoters 54.9%, FIIs 6.8%, DIIs 20.3%, Public 18.0%.Mar '26: Promoters 53.9%, FIIs 6.4%, DIIs 20.4%, Public 19.3%.Jun '26: Promoters 54.1%, FIIs 5.8%, DIIs 20.7%, Public 19.4%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- HSBC Mutual Fund - HSBC Small Cap Fund Mutual fund newly disclosed 1.03% held
- Franklin India Small Cap Fund Mutual fund +0.23 pp 4.29% held
- Amit Indubhusan Bakshi +0.22 pp 42.34% held
The same filing shows 2 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Eris Lifesciences Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Amit Indubhusan Bakshi | 42.34% | +0.22 pp |
| Lilac Investments Limited | 8.63% | unchanged |
| HDFC Small Cap Fund Mutual fund | 8.33% | −0.13 pp |
| Rajendrakumar Rambhai Patel | 4.29% | unchanged |
| Inderjeet Singh Negi | 4.29% | unchanged |
| Franklin India Small Cap Fund Mutual fund | 4.29% | +0.23 pp |
| Kaushal Kamleshkumar Shah | 3.22% | unchanged |
| Hetal Rasiklal Shah | 2.12% | unchanged |
| Bhikhalal Chimanlal Shah | 1.93% | unchanged |
| Naishadh Vikram Shah | 1.66% | unchanged |
| UTI-Flexi Cap Fund Mutual fund | 1.58% | −0.34 pp |
| Rakesh Shah | 1.43% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in ERIS
Filings to Aug 2026
0 new, 4 added, 2 trimmed, 0 sold out — net −0.97 L shares (−0.8%).
- Held by funds
- ₹1.6k Cr
- 13 schemes
- Biggest holder
- HDFC Small Cap Fund
- ₹876 Cr · 2.1% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| HDFC Small Cap Fund HDFC Mutual Fund | ₹876 Cr | −0.99 L | Jul '23 |
| HDFC Hybrid Equity Fund HDFC Mutual Fund | ₹333 Cr | held | Dec '23 |
| HDFC Multi Cap Fund HDFC Mutual Fund | ₹92 Cr | held | Jul '23 |
| HDFC Large and Mid Cap Fund HDFC Mutual Fund | ₹91 Cr | held | Jul '23 |
| HDFC Manufacturing Fund HDFC Mutual Fund | ₹51 Cr | held | May '24 |
| HDFC Business Cycle Fund HDFC Mutual Fund | ₹51 Cr | held | May '25 |
| HDFC Pharma and Healthcare Fund HDFC Mutual Fund | ₹37 Cr | held | Nov '23 |
| Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund | ₹11 Cr | +0.01 L | Apr '23 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
4 added, 2 trimmed — net −97,284 shares (−0.8%)
- Funds are sitting on
- +53%
- vs est. average cost
- Held by funds
- ₹1.6k Cr
- 13 schemes · ≈ 9.0% of the company
- Biggest holder
- HDFC Small Cap Fund
- ₹876 Cr · 2.1% of that fund
- Longest holder
- Nippon India Nifty Smallcap 250 Index Fund
- 3y 5m · since Apr '23
Shares held by these funds +121%
Aug '23 1.15 cr shares Jul '26
All earnings calls (8)
Read the Q1 FY27 call →Learn to analyse Eris Lifesciences Limited
Guides on how to read this kind of business and the numbers that matter.